PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Müller, T.D. ; Blüher, M. ; Tschöp, M.H. ; DiMarchi, R.D.*

Anti-obesity drug discovery: Advances and challenges.

Nat. Rev. Drug Discov. 21, 201-223 (2022)
Verlagsversion DOI PMC
Open Access Hybrid
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
112.288
13.116
3
110
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Glucagon-like Peptide-1; Diet-induced Obese; Growth-factor 21; Body-mass Index; Term Weight Control; Cardiovascular Risk-factors; Improves Glycemic Control; Semaglutide 2.4 Mg; Dependent Insulinotropic Polypeptide; Cannabinoid-1 Receptor Blocker
Sprache englisch
Veröffentlichungsjahr 2022
Prepublished im Jahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1474-1776
Zeitschrift Nature Reviews - Drug Discovery
Quellenangaben Band: 21, Heft: 3, Seiten: 201-223 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-506501-001
G-502200-001
Förderungen German Research Foundation
German Center for Diabetes Research (DZD e.V.)
European Research Council (ERC)
Alexander von Humboldt Foundation
DOI 10.1038/s41573-021-00337-8
WOS ID WOS:000765776100011
WOS ID WOS:000721634800001
Scopus ID 85119702886
PubMed ID 34815532
Erfassungsdatum 2021-12-17
[➜Korrektur melden]